schliessen

Filtern

 

Bibliotheken

Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study

The prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalen... Full description

Journal Title: The Lancet (British edition) 1999, Vol.354 (9192), p.1771-1775
Main Author: Schrag, A
Other Authors: Ben-Shlomo, Y , Quinn, NP
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Elsevier Ltd
ID: ISSN: 0140-6736
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_69306343
title: Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
format: Article
creator:
  • Schrag, A
  • Ben-Shlomo, Y
  • Quinn, NP
subjects:
  • Abridged Index Medicus
  • Aged
  • Aged, 80 and over
  • Atrophy
  • Biological and medical sciences
  • Cross-Sectional Studies
  • Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
  • Diagnosis
  • Female
  • Humans
  • London - epidemiology
  • Male
  • Medical Records Systems, Computerized
  • Medical sciences
  • Middle Aged
  • Multiple System Atrophy - diagnosis
  • Multiple System Atrophy - epidemiology
  • Neurology
  • Parkinson's disease
  • Prevalence
  • Progressive supranuclear palsy
  • Supranuclear Palsy, Progressive - diagnosis
  • Supranuclear Palsy, Progressive - epidemiology
ispartof: The Lancet (British edition), 1999, Vol.354 (9192), p.1771-1775
description: The prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. The participation rate was 84%. The age-adjusted prevalence for PSP was 6·4 per 100000 (five probable and one possible case [95% Cl 2·3–10·6]) and for MSA 4·4 per 100000 (two probable and two possible cases [1·2–7·6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.441412
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_69306343
sourceformatXML
sourcesystemPC
galeidA57820948
sourcerecordidA57820948
originalsourceidFETCH-LOGICAL-c586t-3f915f40b17b98fe47e8157656bdf51f6787b146ed0d6ff8bfc92aff495646793
addsrcrecordideNqNkmuL1DAUhoso7rj6E5SiIop2Tba5NLsfZFm8wYKCCn4LaXoyG-nNnHag_950Ougoykg-FNLnvEnOeZLkPiUnlFDx8hOhjGRC5uKpUs8Io7nM1I1kRZlkGWfy681k9RM5Su4gfiOEMEH47eSIEi6lyItVYj4G2JgaWgtp59I-dOsAiH4DKY59MO1oazAh7U2NU2raKm3GevB9Hf9POECTmiF0_fV0lprUhg4xQ7CD71pTpziM1XQ3ueViMdzbfY-TL29ef758l119ePv-8uIqs7wQQ5Y7RbljpKSyVIUDJqGgXAouyspx6oQsZEmZgIpUwrmidFadGueY4oIJqfLj5MmSG9_wfQQcdOPRQl2bFroRtVA5ETnLI_hwAdfx3dq3rhuCsTOsL7gsToliRYQe_ROiiueKccojlf2FiquCxtuuBefj_n7qyf_w-wc83ysoR_TtPJ0W_fp6wLUZEX-Lf3GY3g_nC76dWwCn--AbEyZNiZ4l01vJ9GyQVkpvJdNzpx_sOj2WDVR7VYtVEXi8AwxaU7uokfX4i6NxXGTGzv843_rBzO7Ervj64C1eLdUQpdp4CBqtnz2ufIgG6qrzBxJ-ABEf_yU
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid69306343
display
typearticle
titlePrevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
sourceAlma/SFX Local Collection
creatorSchrag, A ; Ben-Shlomo, Y ; Quinn, NP
creatorcontribSchrag, A ; Ben-Shlomo, Y ; Quinn, NP
descriptionThe prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. The participation rate was 84%. The age-adjusted prevalence for PSP was 6·4 per 100000 (five probable and one possible case [95% Cl 2·3–10·6]) and for MSA 4·4 per 100000 (two probable and two possible cases [1·2–7·6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(99)04137-9
3PMID: 10577638
4CODEN: LANCAO
languageeng
publisherLondon: Elsevier Ltd
subjectAbridged Index Medicus ; Aged ; Aged, 80 and over ; Atrophy ; Biological and medical sciences ; Cross-Sectional Studies ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Diagnosis ; Female ; Humans ; London - epidemiology ; Male ; Medical Records Systems, Computerized ; Medical sciences ; Middle Aged ; Multiple System Atrophy - diagnosis ; Multiple System Atrophy - epidemiology ; Neurology ; Parkinson's disease ; Prevalence ; Progressive supranuclear palsy ; Supranuclear Palsy, Progressive - diagnosis ; Supranuclear Palsy, Progressive - epidemiology
ispartofThe Lancet (British edition), 1999, Vol.354 (9192), p.1771-1775
rights
01999 Elsevier Ltd
12000 INIST-CNRS
2COPYRIGHT 1999 Elsevier B.V.
lds50peer_reviewed
citedbyFETCH-LOGICAL-c586t-3f915f40b17b98fe47e8157656bdf51f6787b146ed0d6ff8bfc92aff495646793
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1179308$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10577638$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Schrag, A
1Ben-Shlomo, Y
2Quinn, NP
title
0Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
1The Lancet (British edition)
addtitleLancet
descriptionThe prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. The participation rate was 84%. The age-adjusted prevalence for PSP was 6·4 per 100000 (five probable and one possible case [95% Cl 2·3–10·6]) and for MSA 4·4 per 100000 (two probable and two possible cases [1·2–7·6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.
subject
0Abridged Index Medicus
1Aged
2Aged, 80 and over
3Atrophy
4Biological and medical sciences
5Cross-Sectional Studies
6Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
7Diagnosis
8Female
9Humans
10London - epidemiology
11Male
12Medical Records Systems, Computerized
13Medical sciences
14Middle Aged
15Multiple System Atrophy - diagnosis
16Multiple System Atrophy - epidemiology
17Neurology
18Parkinson's disease
19Prevalence
20Progressive supranuclear palsy
21Supranuclear Palsy, Progressive - diagnosis
22Supranuclear Palsy, Progressive - epidemiology
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate1999
recordtypearticle
recordideNqNkmuL1DAUhoso7rj6E5SiIop2Tba5NLsfZFm8wYKCCn4LaXoyG-nNnHag_950Ougoykg-FNLnvEnOeZLkPiUnlFDx8hOhjGRC5uKpUs8Io7nM1I1kRZlkGWfy681k9RM5Su4gfiOEMEH47eSIEi6lyItVYj4G2JgaWgtp59I-dOsAiH4DKY59MO1oazAh7U2NU2raKm3GevB9Hf9POECTmiF0_fV0lprUhg4xQ7CD71pTpziM1XQ3ueViMdzbfY-TL29ef758l119ePv-8uIqs7wQQ5Y7RbljpKSyVIUDJqGgXAouyspx6oQsZEmZgIpUwrmidFadGueY4oIJqfLj5MmSG9_wfQQcdOPRQl2bFroRtVA5ETnLI_hwAdfx3dq3rhuCsTOsL7gsToliRYQe_ROiiueKccojlf2FiquCxtuuBefj_n7qyf_w-wc83ysoR_TtPJ0W_fp6wLUZEX-Lf3GY3g_nC76dWwCn--AbEyZNiZ4l01vJ9GyQVkpvJdNzpx_sOj2WDVR7VYtVEXi8AwxaU7uokfX4i6NxXGTGzv843_rBzO7Ervj64C1eLdUQpdp4CBqtnz2ufIgG6qrzBxJ-ABEf_yU
startdate1999
enddate1999
creator
0Schrag, A
1Ben-Shlomo, Y
2Quinn, NP
general
0Elsevier Ltd
1Lancet
2Elsevier B.V
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
107X8
sort
creationdate1999
titlePrevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
authorSchrag, A ; Ben-Shlomo, Y ; Quinn, NP
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c586t-3f915f40b17b98fe47e8157656bdf51f6787b146ed0d6ff8bfc92aff495646793
rsrctypearticles
prefilterarticles
languageeng
creationdate1999
topic
0Abridged Index Medicus
1Aged
2Aged, 80 and over
3Atrophy
4Biological and medical sciences
5Cross-Sectional Studies
6Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
7Diagnosis
8Female
9Humans
10London - epidemiology
11Male
12Medical Records Systems, Computerized
13Medical sciences
14Middle Aged
15Multiple System Atrophy - diagnosis
16Multiple System Atrophy - epidemiology
17Neurology
18Parkinson's disease
19Prevalence
20Progressive supranuclear palsy
21Supranuclear Palsy, Progressive - diagnosis
22Supranuclear Palsy, Progressive - epidemiology
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Schrag, A
1Ben-Shlomo, Y
2Quinn, NP
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Schrag, A
1Ben-Shlomo, Y
2Quinn, NP
formatjournal
genrearticle
ristypeJOUR
atitlePrevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
jtitleThe Lancet (British edition)
addtitleLancet
date1999
risdate1999
volume354
issue9192
spage1771
epage1775
pages1771-1775
issn0140-6736
eissn1474-547X
codenLANCAO
abstractThe prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. The participation rate was 84%. The age-adjusted prevalence for PSP was 6·4 per 100000 (five probable and one possible case [95% Cl 2·3–10·6]) and for MSA 4·4 per 100000 (two probable and two possible cases [1·2–7·6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.
copLondon
pubElsevier Ltd
pmid10577638
doi10.1016/S0140-6736(99)04137-9